Raymond James reiterates Universal Health Services stock rating

Raymond James maintained a Market Perform rating on Universal Health Services (UHS), citing Q3 results slightly below expectations and a cautious 2027 outlook. UHS stock is down 21% YTD, trading at $172.18. Analysts have lowered earnings estimates due to slower growth at new facilities. Despite near-term challenges, UHS is trading at a P/E ratio of 6.89, suggesting potential undervaluation.

Original reporting
Published Oct 29, 2026, 11:26 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 11:42 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$UHS
Bearish
medium confidence
Mentioned
$UHS
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$UHSBearishMed
01

Why it matters

The mixed earnings and lowered outlook drive short‑term downside, but the beat and low valuation could attract value investors.

02

Market read

UHS earnings and guidance revision are the primary market-moving elements; sector peers may be impacted by policy overhangs.

03

What to watch

Potential upside from upcoming facility ramps and possible policy relief for Medicaid.

Relevance 8/10Novelty 8/10Timing: post‑earnings today

Background

Raymond James provided an analyst note reiterating a Market Perform rating amid mixed Q3 results for Universal Health Services.

Company-level read

Ticker impact

$UHSBearishMedium confidence
Context

Raymond James reiterated a Market Perform rating on UHS after Q3 earnings beat expectations but lowered outlook, causing the stock to fall 8.5% this week.

Expected impact

likely pressure as investors price in weaker guidance and policy overhangs

Evidence & confidence

The earnings beat is offset by a cautious outlook for 2027 and a rating reiteration, which historically triggers short-term sell pressure.

Market effects

The healthcare services sector may see broader scrutiny of Medicaid policy risks.

U.S. hospital operators could face similar valuation pressure.

Limited to U.S. healthcare equities.

Counterpoint

The earnings beat and low P/E suggest undervaluation; the stock may rebound if guidance improves.

Key entities

  • Universal Health Services

    U.S. healthcare services provider (ticker UHS).

  • Raymond James

    Equity research firm issuing the rating.

Related articles

$HCAMed

Hospital Stocks Soared as Democrats Took Congress

HCA Healthcare (HCA) rose 10.34% to $510.70 on November 4, 2026, following Democratic gains in the U.S. election. Investors anticipate potential policy changes favoring hospitals and Medicaid insurers. Universal Health Services (UHS) and Tenet Healthcare (THC) also saw significant gains. HCA's stock is now valued at $106.68 billion, but analysts warn of potential downside risks if policy changes do not materialize.

$CNCMed

Health insurers, hospitals rally after sweeping midterm win for Democrats

Shares of Medicaid-focused health insurers (Centene, Elevance, Molina) and hospital operators (HCA, Tenet, Universal) rose after Democrats won the midterms, raising hopes for sector-friendly policies. Analysts expect delays in Trump's OBBBA, easing pressure on Medicaid and ACA insurers, and potential extensions of enhanced subsidies. Year-to-date gains vary among companies.

$UHSHighAI 8/10

Softer surgery volumes, hospital woes dampened UHS’ Q3 earnings

Universal Health Services (UHS) lowered its 2026 earnings expectations due to declining surgeries and struggles at some hospitals. Q3 net income fell 17% to $308M, while revenues rose 5% to $4.7B. Challenges include lower surgery volumes, delays in new hospital profitability, and rising uninsured patients. UHS expects to be at the lower end of its guidance range for 2024.

$UHSMed

Guggenheim cuts Universal Health Services stock price target to $201 on weak Q3

Guggenheim reduced its price target for Universal Health Services (UHS) to $201 from $209, citing weak Q3 2026 EBITDA and macro pressures. UHS stock is down 8.5% in a week. The company lowered its 2026 EBITDA guidance but sees potential upside from expansions. UHS reported Q3 EPS of $5.22 and revenue of $4.73B, slightly beating estimates. Raymond James kept a Market Perform rating, noting softer profit trends and a cautious 2027 outlook.